Cervical dysplasia is precancerous changes of the cells that make up the lining of the cervix, the opening to the womb (uterus). These changes are detected by microscopic analysis of cell samples which are taken from the cervix during a pelvic exam. Squamous intraepithelial lesion is the pathology term that is used to refer to cervical dysplasia which is observed in smears of cells taken from the cervix. Cervical dysplasia is caused by infection with the human papillomavirus (HPV). HPV is a very common infection that is transmitted through sexual contact. Most new HPV infections occur in young (ages 15-25) women. Most HPV infections do not produce any symptoms and resolve spontaneously.

Market Dynamics:

Increasing organic strategies by the key market players is expected to drive the market growth over the forecast period. For instance, on March 1, 2021, INOVIO, a biotechnology company focused on bringing to market precisely designed deoxyribonucleic acid (DNA)medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, announced that it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials evaluating the safety, tolerability, and efficacy of VGX-3100 to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL) using the company's proprietary CELLECTRA 5PSP device.

Cervical Dysplasia Market Detailed Segmentation:

• By Diagnosis Type
  • Diagnosis Test
    • HPV Test
    • Pap Smear Test
    • Biopsy Test
  • Diagnostic Device
    • Colposcope
• By End User
  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgery Centers
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Top Companies in Cervical Dysplasia Market:
  • Roche
  • Qiagen
  • Abbott Laboratories
  • BD
  • Hologic
  • Seegene
  • Arbor Vita
  • Femasys
  • Cooper Surgical